Case Report: Favorable Efficacy of Combined Afatinib and Anlotinib Treatment in a Lung Adenocarcinoma Patient Harboring Uncommon L858M/L861R Mutations

Overview

Journal Front Pharmacol

Date 2024 Dec 16

PMID 39679364

Authors

Yueming He

Yitao Wu

Rongqi He

Meng Xu

Heshan Chen

Yiran Meng

Liuqing Zheng

Li Wang

Affiliations

Soon will be listed here.

Abstract

Targeted therapy has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients carrying common mutations, but the standard care for patients with rare mutations has not been well established. Here, we report a 65-year-old female diagnosed with stage IIIC lung adenocarcinoma located in the right inferior lobe, harboring uncommon L858M/L861R mutations. Remarkably, 24 days post-treatment of afatinib and anlotinib, chest CT scans demonstrated significant shrinkage of primary lesion, indicating a partial response. Except for mild hand-foot syndrome and diarrhea, no other severe adverse symptoms were observed throughout treatment. The patient, now on combination therapy for exceeding 12 months, exhibits further decreased tumor size and a high quality of life. This case underscores the importance of precise molecular diagnosis in guiding therapeutic strategies and provides a valuable reference for clinical decision-making in EGFR-positive NSCLC cases with atypical mutations.

References

Chu T, Zhang W, Zhang B, Zhong R, Zhang X, Gu A . Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Transl Lung Cancer Res. 2022; 11(7):1394-1404. PMC: 9359953. DOI: 10.21037/tlcr-22-438. View

Saxon J, Sholl L, Janne P . EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. J Thorac Oncol. 2017; 12(5):884-889. PMC: 5558893. DOI: 10.1016/j.jtho.2017.01.006. View

Pennell N, Lynch Jr T . Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009; 14(4):399-411. DOI: 10.1634/theoncologist.2008-0276. View

Kobayashi Y, Mitsudomi T . Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016; 107(9):1179-86. PMC: 5021039. DOI: 10.1111/cas.12996. View

Yang J, Sequist L, Geater S, Tsai C, Mok T, Schuler M . Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015; 16(7):830-8. DOI: 10.1016/S1470-2045(15)00026-1. View

Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K . Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 1995; 71(1):160-5. PMC: 2033433. DOI: 10.1038/bjc.1995.33. View

Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C . Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharmacol Res. 2023; 188:106668. DOI: 10.1016/j.phrs.2023.106668. View

Zhang L, Wang L, Wang J, Chen J, Meng Z, Liu Z . Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study. Mol Cancer. 2023; 22(1):124. PMC: 10403846. DOI: 10.1186/s12943-023-01823-w. View

Abdelmaksoud-Dammak R, Ammous-Boukhris N, Saadallah-Kallel A, Charfi S, Khemiri S, Khemakhem R . Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. Genes (Basel). 2022; 13(8). PMC: 9407939. DOI: 10.3390/genes13081499. View

10.

Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S . Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20(5):625-635. DOI: 10.1016/S1470-2045(19)30035-X. View

11.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

12.

Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S . Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014; 9(2):189-94. PMC: 4132025. DOI: 10.1097/JTO.0000000000000048. View

13.

Alvarez-Aznar A, Muhl L, Gaengel K . VEGF Receptor Tyrosine Kinases: Key Regulators of Vascular Function. Curr Top Dev Biol. 2017; 123:433-482. DOI: 10.1016/bs.ctdb.2016.10.001. View

14.

Hirsch F, Varella-Garcia M, Bunn Jr P, Di Maria M, Veve R, Bremmes R . Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21(20):3798-807. DOI: 10.1200/JCO.2003.11.069. View

15.

Horn L, Sandler A . Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res. 2009; 15(16):5040-8. PMC: 3528182. DOI: 10.1158/1078-0432.CCR-09-0520. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z . Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018; 4(11):1569-1575. PMC: 6248083. DOI: 10.1001/jamaoncol.2018.3039. View

18.

Yang J, Schuler M, Popat S, Miura S, Heeke S, Park K . Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020; 15(5):803-815. DOI: 10.1016/j.jtho.2019.12.126. View

19.

Berge E, Aisner D, Doebele R . Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol. 2013; 8(9):e83-4. PMC: 4154819. DOI: 10.1097/JTO.0b013e31829ceb8d. View

20.

Tabernero J . The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007; 5(3):203-20. DOI: 10.1158/1541-7786.MCR-06-0404. View